Literature DB >> 10699185

Expression of the human CFTR gene from episomal oriP-EBNA1-YACs in mouse cells.

D Huertas1, S Howe, A McGuigan, C Huxley.   

Abstract

Plasmids carrying the origin of plasmid replication ( oriP ) and expressing the EBNA-1 protein from the Epstein-Barr virus replicate and segregate in human cells and are thus potentially useful vectors for gene therapy. As very large circular molecules, up to 660 kb in size, can be maintained episomally using this system, it is possible to include intact human genes with all their long-range controlling elements which might give high levels of tissue-specific and controlled gene expression. We have shown previously that a 320 kb yeast artificial chromosome (YAC) carrying the intact human CFTR gene can complement the Cambridge null cystic fibrosis mice as a transgene. We have now modified this YAC to a circular molecule carrying both oriP and the EBNA-1 gene. We show that this oriP-EBNA1-YAC can be stably maintained as unrearranged episomes in mouse LA-9 cells, which do not express endogenous cftr, and in mouse CMT-93 cells, which do express endogenous cftr. The human CFTR gene is expressed in some of the cell lines, but the level of expression is very variable between cell lines and is not related to the copy number of the elements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699185     DOI: 10.1093/hmg/9.4.617

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  An S/MAR-based L1 retrotransposition cassette mediates sustained levels of insertional mutagenesis without suffering from epigenetic silencing of DNA methylation.

Authors:  Danny Rangasamy
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

Review 2.  The manipulation of chromosomes by mankind: the uses of microcell-mediated chromosome transfer.

Authors:  Karen J Meaburn; Christopher N Parris; Joanna M Bridger
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

3.  Bacterial delivery of large intact genomic-DNA-containing BACs into mammalian cells.

Authors:  Wing Cheung; George Kotzamanis; Hassan Abdulrazzak; Sylvie Goussard; Tadashi Kaname; Athanassios Kotsinas; Vassilis G Gorgoulis; Catherine Grillot-Courvalin; Clare Huxley
Journal:  Bioeng Bugs       Date:  2012-03-01

4.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

5.  Retrofitting BACs with G418 resistance, luciferase, and oriP and EBNA-1 - new vectors for in vitro and in vivo delivery.

Authors:  Christine Magin-Lachmann; George Kotzamanis; Leonardo D'Aiuto; Ernst Wagner; Clare Huxley
Journal:  BMC Biotechnol       Date:  2003-02-03       Impact factor: 2.563

Review 6.  Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

Authors:  Stefano Ferrari; Duncan M Geddes; Eric W F W Alton
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

7.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

8.  Regulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells.

Authors:  Hanne A Askautrud; Elisabet Gjernes; Gro L Størvold; Mona M Lindeberg; Jim Thorsen; Hans Prydz; Eirik Frengen
Journal:  BMC Biotechnol       Date:  2009-10-16       Impact factor: 2.563

9.  CFTR expression from a BAC carrying the complete human gene and associated regulatory elements.

Authors:  George Kotzamanis; Hassan Abdulrazzak; Jennifer Gifford-Garner; Pei Ling Haussecker; Wing Cheung; Catherine Grillot-Courvalin; Ann Harris; Christos Kittas; Athanasios Kotsinas; Vassilis G Gorgoulis; Clare Huxley
Journal:  J Cell Mol Med       Date:  2008-07-24       Impact factor: 5.310

Review 10.  Gene therapy progress and prospects: cystic fibrosis.

Authors:  U Griesenbach; S Ferrari; D M Geddes; E W F W Alton
Journal:  Gene Ther       Date:  2002-10       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.